FIELD: medicine.SUBSTANCE: invention relates to a method of treating glioblastoma in a subject by administering a therapeutically effective amount of an antibody or antigen-binding portion thereof, which specifically binds to the programmed death-1 receptor (PD-1) and inhibits PD-1 ('anti-PD-1'), and temozolomide activity.EFFECT: method enables higher clinical effectiveness in glioblastoma ensured by a synergistic effect of the combination.53 cl, 17 dwg, 1 tbl, 10 ex
USE OF INHIBITORS OF IMMUNE CONTROL POINTS IN NEW GROWTHS OF CENTRAL NERVOUS SYSTEM